Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors

• Choose appropriate patients with advanced solid cancers, with written consent for this study;
• Perform biopsy to get fresh sample for DNA/RNA-seqencings and bioinformatics analysis;
• Produce appropriate polypeptide vaccine for human use and deliver the vaccine into selected patients via local injections, and follow up closely to collect related results as required;
• To enhance the killing capability, cotreatment the patients with PD1/PDL1/CTLA4 antibodies may be applied;
• Evaluate the clinical results as needed.

Inclusion criteria

• Patients with advanced cancer; 2. Life expectancy >12 weeks; 3. Adequate heart, lung, liver, kidney, and blood function; 4. Available high quality vaccine for human use; 5. Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent.

-

Exclusion criteria

• Had accepted gene therapy before;
• Severe virus infection such as HBV, HCV, HIV, et al;
• Known HIV positivity;
• Active infectious disease related to bacteria, virus,fungi,et al;
• Other severe diseases that the investigators consider not appropriate;
• Pregnant or lactating women;
• Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent/kg/day);
• Other conditions that the investigators consider not appropriate.